Sedatives and Hypnotics

Chapter

Abstract

Insomnia is a subjective complaint of poor sleep that may lead to problems with daytime functioning. Sedatives and hypnotics have been the treatments of choice for decades. Benzodiazepines have shown the most evidence for effective treatment. However, they have serious side effects which include falls, confusion, rebound insomnia, tolerance, and potential for abuse. There have been newer medications that have sought to be just as effective without the inherent side effects. Thoughts of treatment length, acute versus chronic, continue to be discussed. Diagnosis and management can be complex especially when patients have multiple comorbid conditions. This chapter will discuss the uses of hypnotics and sedatives for the treatment of insomnia. As well as outline appropriate management strategies for effective treatment outcomes.

Keywords

Insomnia Sleep and sedatives Sedative and sleep Hypnotics Benzodiazepines Treatment considerations for insomnia 

References

  1. 1.
    Léger D, Poursain B, Neubauer D, Uchiyama M. An international survey of sleeping problems in the general population. Curr Med Res Opin. 2008;24(1):307–17.CrossRefGoogle Scholar
  2. 2.
    Neubauer D, Flaherty K. Chronic insomnia. Semin Neurol. 2009;29(4):340–53.CrossRefGoogle Scholar
  3. 3.
    Panossian L, Avidan A. Sleep disorders in neurologic practice: a case-based approach. Neurol Clin. 2016;34(3):565–94.CrossRefGoogle Scholar
  4. 4.
    Quigga M, Gharaib S, Rulandb J, Schroeder C, Hodges M, Ingersoll K. Insomnia in epilepsy is associated with continuing seizures and worse quality of life. Epilepsy Res. 2016;122:91–6.CrossRefGoogle Scholar
  5. 5.
    Wu M, Lin H, Weng S, Ho C, Wang J, Hsu Y. Insomnia subtypes and the subsequent risks of stroke: report from a nationally representative cohort. Stroke. 2014;45:1349–54.CrossRefGoogle Scholar
  6. 6.
    Institute of Medicine (US) Committee on Sleep Medicine and Research. Sleep physiology. In: Altevogt B, Colten HR, editors. Sleep disorders and sleep deprivation: an unmet public health problem. Washington, DC: National Academies Press (US); 2006.Google Scholar
  7. 7.
    Irwin M. Why sleep is important for health: a psychoneuroimmunology perspective. Annul Rev Psychol. 2015;66:143–72.CrossRefGoogle Scholar
  8. 8.
    Poyares D, Guilleminault C, Ohayon M, Tufik S. Chronic benzodiazepine usage and withdrawal insomnia patients. J Psychiatr Res. 2004;38(3):327–34.CrossRefGoogle Scholar
  9. 9.
    American Academy of Sleep Medicine. In: Darien IL, editor. International classification of sleep disorders. Weschester: American Academy of sleep medicine; 2014.Google Scholar
  10. 10.
    National Institutes of Health. National institutes of health state of the science conference statement on manifestations and management of chronic insomnia in adults. Bethesda: NIH; 2005.Google Scholar
  11. 11.
    Hollister LE. The pre-benzodiazepine era. J Psychoactive Drugs. 1983;15:9–13.CrossRefGoogle Scholar
  12. 12.
    Lopez-Munoz F, Ucha-Udabe R, Alamo C. The history of barbiturates a century after their clinical introduction. Neuropsychiatr Dis Treat. 2005;1(4):329–43.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Committee NE. Expert committee on addiction-producing drugs. Geneva: World Health Organization; 1956.Google Scholar
  14. 14.
    Wick J. The history of benzodiazepines. Consult Pharm. 2013;28(9):538–48.CrossRefGoogle Scholar
  15. 15.
    Rosenbaum J. Attitudes toward benzodiazepines over the years. J Clin Psychiatry. 2005;66:4–8.PubMedGoogle Scholar
  16. 16.
    Hilty D, Young J. Algorithms from assessment and management of insomnia in primary care. Patient Prefer Adherence. 2009;3:9–20.CrossRefGoogle Scholar
  17. 17.
    Mitchell M, Gehrman P, Perlis M, Umscheid C. Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. BMC Fam Pract. 2012;13:40.CrossRefGoogle Scholar
  18. 18.
    Benca RM. Diagnosis and treatment of chronic insomnia: a review. Psychiatr Serv. 2005;56(3):332–43.CrossRefGoogle Scholar
  19. 19.
    Buysse D. Insomia. JAMA. 2013;309(7):706–16.CrossRefGoogle Scholar
  20. 20.
    FDA. U.S. Drug and Food Adminstration. 2015. Retrieved Jan 9, 2017, from http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm101557.htm
  21. 21.
    Krystal AD. A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice. Sleep Med Rev. 2009;13(4):265–74.CrossRefGoogle Scholar
  22. 22.
    Mitler M. Evaluation of temazepam as a hypnotic. Pharmacotherapy. 1981;1(1):3–13.CrossRefGoogle Scholar
  23. 23.
    Roehrst T, Zorick F, Lord N, Koshorek G, Roth T. Dose-related effects of estazolam on sleep of patients with insomnia. J Clin Psychopharmacol. 1983;3(3):152–6.Google Scholar
  24. 24.
    Pierce M, Shu V. Efficacy of estazolam. The United States clinical experience. Am J Med. 1990;88(3A):6s–11s.CrossRefGoogle Scholar
  25. 25.
    Vogel G, Morris D. The effects of estazolam on sleep, performance, and memory: a long-term sleep laboratory study of elderly insomniacs. J Clin Pharmacol. 1992;32(7):647–51.CrossRefGoogle Scholar
  26. 26.
    Scharf M, Roth P, Dominguez R, Ware J. Estazolam and flurazepam: a multicenter, placebo-controlled comparative study in outpatients with insomnia. J Clin Pharmacol. 1990;30 (5):461–7.CrossRefGoogle Scholar
  27. 27.
    Roehrs T, Zorick F, Kaffeman M, Sicklesteel J, Roth T. Flurazepam for short-term treatment of complaints of insomnia. J Clin Pharmacol. 1982;22(7):290–6.CrossRefGoogle Scholar
  28. 28.
    Pakes G, Brogden R, Heel R, Speight T, Avery G. Triazolam: a review of its pharmacological properties and therapeutic efficacy in patients with insomnia. Drugs. 1981;22(2):81–110.CrossRefGoogle Scholar
  29. 29.
    Kroboth P, Juhl R. New drug evaluations. Triazolam. Drug Intell Clin Pharm. 1983;17(7):495–500.CrossRefGoogle Scholar
  30. 30.
    Kales A. Quazepam: hypnotic efficacy and side effects. Pharmacotherapy. 1990;10(1):1–10. discussion 10-2.PubMedGoogle Scholar
  31. 31.
    Dündar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A. Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. Health Technol Assess. 2004;8(24):1–125.CrossRefGoogle Scholar
  32. 32.
    Mohler H, Fritschy J, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol ExperTher. 2002;300(1):2–8.CrossRefGoogle Scholar
  33. 33.
    Hoehns J, Perry P. Zolpidem: a benzodiazepine hypnotic for treatment of insomnia. Clin Pharmacol. 1993;12(11):814–28.Google Scholar
  34. 34.
    Merlotti L, Roehrs T, Koshorek G, Zorick F, Lamphere J, Roth T. The dose effects of zolpidem on the sleep of healthy normals. J Clin Pharm Ther. 1989;9:9–14.Google Scholar
  35. 35.
    MacFarland J, Morin C. Hypnotics and insomnia: the experience of zolpidem. Clin Ther. 2014;36(11):1676–701.CrossRefGoogle Scholar
  36. 36.
    Paulke A, Wunder C, Toennes S. Sleep self-intoxication and sleep driving as rare zolpidem-induced complex behaviour. Int J Legal Med. 2015;129(1):85–8.CrossRefGoogle Scholar
  37. 37.
    Poceta J. Zolpidem ingestion, automatisms, and sleep driving: a clinical and legal case series. J Clin Sleep Med. 2011;7(6):632–8.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Noble S, Langtry H, Lamb H. Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs. 1998;55(2):277–302.CrossRefGoogle Scholar
  39. 39.
    Zammit GK, McNabb L. Efficacy and safety of eszopiclone across six weeks of treatment for primary insomnia. Curr Med Res Opin. 2004;20(12):1979–91.CrossRefGoogle Scholar
  40. 40.
    Walsh J, Krystal A, Amato D, Rubens R, Caron J, Wessel T. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep. 2007;30(8):959–68.CrossRefGoogle Scholar
  41. 41.
    Najib J. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther. 2006;28(4):491–516.CrossRefGoogle Scholar
  42. 42.
    Pinto L Jr, Bittencourt L, Treptow E, Braqa LR, Tufik S. Eszopiclone versus zopiclone in the treatment of insomnia. Clinics (Sao Paulo). 2016;71(1):5–9.CrossRefGoogle Scholar
  43. 43.
    Elie R, Ruther E, Farr I, Emilien G, Salinas E. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. J Clin Psychiatry. 1999;60:536–44.CrossRefGoogle Scholar
  44. 44.
    Israel A, Kramer J. Safety of zaleplon in the treatment of insomnia. Ann Pharmacother. 2002;36(5):852–9.CrossRefGoogle Scholar
  45. 45.
    Roth T, Walsh J, Krystal A, Wessel T, Roehrs TA. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med. 2005;6(6):487–95.CrossRefGoogle Scholar
  46. 46.
    Krystal A, Walsh J, Laska E, Caron J, Amato DA, Wessel T. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003;26(7):793–9.CrossRefGoogle Scholar
  47. 47.
    Randall S, Roehrs T, Roth T. Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study. Sleep. 2012;35(11):1551–7.CrossRefGoogle Scholar
  48. 48.
    Stahl S. Awakening to the psychopharmacology of sleep and arousal: novel neurotransmitters and wake-promoting drugs. J Clin Psychiatry. 2002;63(6):467–8.CrossRefGoogle Scholar
  49. 49.
    Coleman PJ, Gotter A. Tthe discovery of suvorexant, the first Orexin receptor drug for insomnia. Ann Rev Psychopharmacol Toxicol. 2016;57:509–33.CrossRefGoogle Scholar
  50. 50.
    Sutton EL. Profile of suvorexant in the management of insomnia. Drug Des Devel Ther. 2015;9:6035–42.CrossRefGoogle Scholar
  51. 51.
    Merck, Sharp, & Dohme. Belsomra (Survorexant): full prescribing information. 2014. Retrieved Jan 2017, from https://www.merck.com/product/usa/pi_.pdf.
  52. 52.
    Michelson D, Snyder E. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomize, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(5):461–71.CrossRefGoogle Scholar
  53. 53.
    Zhdanova I, Lynch H, Wurtman R. Melatonin: a sleep-promoting hormone. Sleep. 1997;20(10):899–907.PubMedGoogle Scholar
  54. 54.
    Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Interl Med. 2007;22(9):1335–50.CrossRefGoogle Scholar
  55. 55.
    Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005;48(2):301–10.CrossRefGoogle Scholar
  56. 56.
    Erman M, Seiden D, Zammit G, Sainati, Zhang J. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med. 2006;7(1):17–24.CrossRefGoogle Scholar
  57. 57.
    Miyata A, Iwamoto K, Kawano N, Kohmura K, Yamamoto M, Aleksic B. The effects of acute treatment with ramelteon, triazolam, and placebo on driving performance, cognitive function, and equilibrium function in healthy volunteers. Psychopharmacology. 2015;232(12):2127–37.CrossRefGoogle Scholar
  58. 58.
    McCall C, McCall W. What is the role of sedating antidepressants, antipsychotics, and anticonvulsants in the management of insomnia? Curr Psychiatry Rep. 2012;14:494–502.CrossRefGoogle Scholar
  59. 59.
    Mendelson W. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66(4):469–76.CrossRefGoogle Scholar
  60. 60.
    Roth A, McCall W, Liguori A. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. J Sleep Res. 2011;20(4):552–8.CrossRefGoogle Scholar
  61. 61.
    Hajak G, Rodenbeck A, Voderholzer U, Reimann D, Cohrs S, Hohagen F. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry. 2001;62(2):453–63.CrossRefGoogle Scholar
  62. 62.
    Weber J, Siddiqui M, Wagstaff A, McCormack P. Low-dose doxepin: in the treatment of insomnia. CNS Drugs. 2010;24(8):713–20.CrossRefGoogle Scholar
  63. 63.
    de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 1995;10(4):19–23.CrossRefGoogle Scholar
  64. 64.
    Aslan S, Isike E, Cosar B. The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers. Sleep. 2002;25(6):677–9.CrossRefGoogle Scholar
  65. 65.
    Schmid D, Wichniak A, Uhr M, M I, Brunner H, Held K. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology. 2006;31(4):832–44.CrossRefGoogle Scholar
  66. 66.
    Schittecatte M, Dumont F, Machowski R. Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology. 2002;46(4):197–201.CrossRefGoogle Scholar
  67. 67.
    Ivgy-Maya N, Ruweb F, Krystalc A, Roth T. Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a randomized, 6-week sleep laboratory trial. Sleep Med. 2015;16(7):838–44.CrossRefGoogle Scholar
  68. 68.
  69. 69.
    Asnis M, Thomas GM, Henderson M. Pharmacotherapy treatment options for insomnia: a primer for clinicians. Int J Mol Sci. 2015;17(1):50.CrossRefGoogle Scholar
  70. 70.
    Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs. 2004;18:297–328.CrossRefGoogle Scholar
  71. 71.
    Roth T, Hartse K, Saab P. The effects of flurazepam, lorazepam, and triazolam on sleep and memory. Psychopharmacology. 1980;70(3):231–7.CrossRefGoogle Scholar
  72. 72.
    Mets M, Volkerts E, Olivier B, Verste J. Effect of hypnotic drugs on body balance and standing steadiness. Sleep Med Rev. 2010;14:259–67.CrossRefGoogle Scholar
  73. 73.
    Weaver MF. Prescription sedative misuse and abuse. J Biol Med. 2015;88:247–56.Google Scholar
  74. 74.
    Zhabenko N, Wojnar M. Prevalence and correlates of insomnia and a polish sample of alcohol dependent patients. Alcohol Clin Exp Res. 2012;36:1600–7.CrossRefGoogle Scholar
  75. 75.
    Brower KJ, Perron B. Prevalence and correlates of withdrawal-related insomnia among adults with alcohol dependence: results from a national survey. Am J Addict Tab 201023. 2010;19(3):238–44.CrossRefGoogle Scholar
  76. 76.
    Brower KJ. Assessment and treatment of insomnia and adult patients with alcohol use disorder. Alcohol. 2015;49:417–27.CrossRefGoogle Scholar
  77. 77.
    Friedmann PD, Rose J. Trazodone sleep disturbance after alcohol detoxification: a double-blind, placebo-controlled trial. Alcohol: Clin Exp Res. 2008;32(9):1652–60.CrossRefGoogle Scholar
  78. 78.
    Rodriguez J, Dzierzewski J, Alessi CA. Sleep problems in the elderly. Med Clin N Am. 2015;99(2):431–9.CrossRefGoogle Scholar
  79. 79.
    Foley D, Monjan A, Brown S, Simonsick EM, Wallace RB, Blazer D. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep. 1995;18(6):425–32.CrossRefGoogle Scholar
  80. 80.
    Perlis M, Smith L, Lyness JM, Matteson SR, Pigeon WR, Jungquist C. Insomnia as a risk factor for onset of depression in the elderly. Behav Sleep Med. 2006;4(2):104–13.CrossRefGoogle Scholar
  81. 81.
    Wang P, Bohn R, Glynn R, Mogun H, Avorn J. Zolpidem use and hip fractures in older people. J Am Geriatr Soc. 2001;49(12):1685–90.CrossRefGoogle Scholar
  82. 82.
    Kang D, Park S, Rhee C, Kim Y, Choi NK, Lee J. Zolpidem use and risk of fracture in elderly insomnia patients. J Prev Med Public Health. 2012;45(4):219–26.CrossRefGoogle Scholar
  83. 83.
    Ilomäki J, Paljärvi T, Korhonen M, Enlund H, Alderman CP, Kauchanen J. Prevalence of concomitant use of alcohol and sedative-hypnotic drugs in middle and older aged persons: a systematic review. Ann Pharmacother. 2013;47:257–68.CrossRefGoogle Scholar
  84. 84.
    Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4(5):487–504.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Qaseem A, Kansagara D, Forciea M, Cooke M, Denberg T, Physicians, C. G. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Internl Med. 2016;165(2):125–33.CrossRefGoogle Scholar
  86. 86.
    Chung S, Bohnen N, Albin R, Frey KA, Müller ML, Chervin R. Insomnia and sleepiness in Parkinson disease: associations with symptoms and comorbidities. J Clin Sleep Med. 2013;9(11):1131–7.PubMedPubMedCentralGoogle Scholar
  87. 87.
    Ylikoski A, Martikainen K, Sieminski M, Partinen M. Parkinson’s disease and insomnia. Neurol Sci. 2015;36:2003–10.CrossRefGoogle Scholar
  88. 88.
    Gudin J, Mogali S, Jones J, Comer S. Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use. Postgrad Med. 2013;125(4):115–30.CrossRefGoogle Scholar
  89. 89.
    Kalmbach D, Pillai V, Arnedt J, Drake C. Identifying at-risk individuals for insomnia using the ford insomnia response to stress test. Sleep. 2016;39(2):449–4546.CrossRefGoogle Scholar
  90. 90.
    Buysse D, Reynolds C 3rd, Monk T, Berman SR, Kupler DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213.CrossRefGoogle Scholar
  91. 91.
    Moloney M, Konrad T, Zimmer C. The medicalization of sleeplessness: a public health concern. Am J Public Health. 2011;101(8):1429–33.CrossRefGoogle Scholar
  92. 92.
    Heel R, Brogden R, Speight T, Avery G. Temazepam: a review of its pharmacological properties and therapeutic efficacy as an hypnotic. Drugs. 1981;21(5):321–40.CrossRefGoogle Scholar
  93. 93.
    Cohn J, Wilcox C, Bremner J, Ettinger M. Hypnotic efficacy of estazolam compared with flurazepam in outpatients with insomnia. J Clin Pharmacol. 1991;31(8):747–50.CrossRefGoogle Scholar
  94. 94.
    Stahl SM. Essential psychopharmacology: neuroscientific basis and practical applications. 2nd ed. New York: Cambridge University Press; 2000.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Psychiatry and Behavioral NeuroscienceSaint Louis University School of MedicineSt. LouisUSA

Personalised recommendations